Skip to main
LFCR

LFCR Stock Forecast & Price Target

LFCR Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lifecore Biomedical is a fully integrated CDMO that has displayed strong commercial momentum in recent months with several new agreements signed with global pharmaceutical companies, including a new agreement for technical transfer services in the manufacturing of an injectable suspension product for neurological disorders. The company's turnaround phase under CEO Paul Josephs has been completed, and management has stated that it now has the necessary resources to execute its strategic vision. With over 30 active projects in its pipeline, including late-stage and commercial site transfers, Lifecore is expected to see significant revenue growth starting in 2028, with some impact potentially being felt in 2027. Although there are risks to consider, such as failing to meet revenue or earnings estimates, we maintain our OUTPERFORM rating and have increased our 12-month price target to $6.50.

Bears say

Lifecore Biomedical is struggling with significant leverage and a low cash flow, which may impact their ability to handle future tech transfer wins and hinder their potential for growth in the long term. However, the company's leadership has provided some reassurance by affirming their financial guidance, which includes a projected increase in capacity utilization and margin on incremental revenue. These efforts could potentially offset the negative impact of their current financial situation over time.

LFCR has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lifecore Biomedical Inc (LFCR) Forecast

Analysts have given LFCR a Buy based on their latest research and market trends.

According to 1 analysts, LFCR has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lifecore Biomedical Inc (LFCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.